Relief for Indian pharma as US FDA green lights the way

20 April 2020
gateway-of-india-big

Approvals from the US Food and Drug Administration are coming in thick and fast, in what has come as a major relief for Indian pharmaceutical companies. The US health regulator has cleared the manufacturing facilities of four Indian drug majors which were earlier under its lens. Several Indian companies also feature in the FDA's first-time generic drug approval list for 2020, reports The Pharma Letter’s India correspondent.

The COVID-19 pandemic has brought to the fore the intricate inter-dependencies that exist within the international pharmaceutical market. As per a March survey conducted by the Institute for Supply Chain Management, nearly 75% of companies reported supply chain disruptions in one form or the other due to coronavirus-related transportation restrictions.

As supply chain disruptions cause drug shortages across the world, the past fortnight has seen clearances from the US FDA for the manufacturing facilities of four Indian drug companies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics